M., Cummings, N., Larson, L
Last reviewed: 18 Jun 2026 Sources Wegovy tablet, emc [accessed 18 June 2026] Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial, The Lancet [accessed 10 June 2026] Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, The New England Journal of Medicine [accessed 10 June 2026] Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen, emc [accessed 10 June 2026] Wegovy 1.5 mg tablets SmPC/PIL, emc [accessed 18 June 2026] Related weight loss treatments Further reading on Wegovy pill Trusted by thousands Your health guided by experts Our doctors are regulated by the CQC and GPhC, the same bodies overseeing NHS care.
View all 3 sources Wilding JPH et al
Disclaimer: This product is sold explicitly as a chemical reagent for laboratory research and testing purposes only
It exists as a pre-formed heterotetramer of two extracellular alpha subunits and two transmembrane beta subunits linked by disulfide bonds
Pregnant or nursing individuals should consult their healthcare provider before starting glutathione
